ArticleClinical medicine (London, England)2009
Testing challenges: evaluation of novel diagnostics and molecular biomarkers.
Article in Clinical medicine (London, England), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review and Recommendations Around Frameworks for Evaluating Scientific Validity in Nutritional Genomics.Frontiers in nutrition · 2021Pooled it
- Genomic tests to guide management of breast cancer in Europe: regulation, reimbursement, adoption, and challenges.Future oncology (London, England) · 2025Review
- Cardiac biomarkers of acute coronary syndrome: from history to high-sensitive cardiac troponin.Internal and emergency medicine · 2017Article
- Issues concerning the evaluation and regulation of predictive genetic testing.Journal of community genetics · 2014Article
- Next-generation sequencing in the clinic: are we ready?Nature reviews. Genetics · 2012Review
- Making Alzheimer's and dementia research fit for populations.Lancet (London, England) · 2012Article
- The impact of genomics on public health practice: the case for change.Public health genomics · 2012Article
- Evaluation of genetic tests for susceptibility to common complex diseases: why, when and how?Human genetics · 2010Article
- Personalized Medicine Beyond Genomics: New Technologies, Global Health Diplomacy and Anticipatory Governance.Current pharmacogenomics and personalized medicine · 2009Article
- Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology.Biomedicine hubArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Through the lens of public health genomics, this article probes certain issues that concern the evaluation of diagnostic tests and molecular biomarkers, and the accompanying policy and regulatory implications. It begins with some conceptual remarks followed by a discussion of evaluation, translation, and regulation, and their importance for public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.